SBRT 2016

Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell

lung cancer (NSCLC) Lucas Lung Cancer 2014

• • • •

Retrospective study

160 patients

SBRT: 54Gy in 3F

AHRT: 70.2Gy in 26Fx

 No difference in any in OS, RF, DF, LC  No difference in toxicity

 SBRT not fundamentally different, “just” more convenient

Matthias Guckenberger - ESTRO SBRT Course 2016 Athens

13.06.2016

27

/